Simplex Trading
APLS

Simplex Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Simplex Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Sell
77,000
-148,700
-66% -$3.2M ﹤0.01% 1472
2025
Q4 		$5.67M Buy
225,700
+76,600
+51% +$1.8M ﹤0.01% 1190
2025
Q3 		$3.37M Buy
149,100
+5,000
+3% +$117K ﹤0.01% 1823
2025
Q2 		$2.49M Buy
144,100
+67,200
+87% +$1.24M ﹤0.01% 1912
2025
Q1 		$1.68M Sell
76,900
-244,800
-76% -$6.76M ﹤0.01% 2201
2024
Q4 		$10.3M Buy
321,700
+68,000
+27% +$2.04M 0.01% 1011
2024
Q3 		$7.32M Sell
253,700
-3,400
-1% -$126K ﹤0.01% 1232
2024
Q2 		$9.86M Buy
257,100
+147,600
+135% +$6.68M 0.01% 1024
2024
Q1 		$6.44M Sell
109,500
-231,100
-68% -$14.7M ﹤0.01% 1413
2023
Q4 		$20.4M Sell
340,600
-178,600
-34% -$9.06M 0.01% 718
2023
Q3 		$19.8M Buy
519,200
+345,000
+198% +$15.2M 0.02% 594
2023
Q2 		$15.9M Sell
174,200
-4,000
-2% -$345K 0.01% 671
2023
Q1 		$11.8M Buy
178,200
+27,700
+18% +$1.6M 0.01% 815
2022
Q4 		$7.78M Buy
150,500
+131,900
+709% +$7M 0.01% 973
2022
Q3 		$1.27M Sell
18,600
-26,100
-58% -$1.54M ﹤0.01% 2380
2022
Q2 		$2.02M Buy
44,700
+700
+2% +$31.9K ﹤0.01% 1856
2022
Q1 		$2.23M Buy
44,000
+41,000
+1,367% +$1.81M ﹤0.01% 1998
2021
Q4 		$141K Sell
3,000
-14,400
-83% -$567K ﹤0.01% 5694
2021
Q3 		$1.18M Buy
17,400
+1,400
+9% +$78.7K ﹤0.01% 2836
2021
Q2 		$1.01M Buy
16,000
+15,825
+9,043% +$817K ﹤0.01% 3104
2021
Q1 		$750K Buy
+175
New +$8.28K ﹤0.01% 2793
2020
Q3 		– Sell
-396
Closed -$1.29M – 7731
2020
Q2 		$1.29M Buy
396
+319
+414% +$10.2K ﹤0.01% 1896
2020
Q1 		$206K Sell
77
-224
-74% -$7.95K ﹤0.01% 3546
2019
Q4 		$921K Buy
301
+292
+3,244% +$8.08K ﹤0.01% 2167
2019
Q3 		$21K Buy
9
+7
+350% +$193 ﹤0.01% 5761
2019
Q2 		$5K Buy
+2
New +$41 ﹤0.01% 6433

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Simplex Trading's APLS Position: Q1 2026 in Review

Simplex Trading reduced its Apellis Pharmaceuticals (APLS) stake by 90% in Q1 2026, selling an estimated $527K and leaving 2,735 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #4966.

Simplex Trading first reported a position in APLS in Q2 2019 and has held it in 19 quarters since. The position peaked at $6.92M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Simplex Trading held 2,735 shares of Apellis Pharmaceuticals worth $110K as of Q1 2026.
  • Simplex Trading sold 24,452 Apellis Pharmaceuticals shares in Q1 2026, an estimated $527K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4966 holding.
  • Simplex Trading first reported a position in Apellis Pharmaceuticals in Q2 2019 and has held it in 19 quarters since.
  • Simplex Trading's Apellis Pharmaceuticals position peaked at $6.92M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.